J. Medioni

522 total citations
11 papers, 88 citations indexed

About

J. Medioni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, J. Medioni has authored 11 papers receiving a total of 88 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in J. Medioni's work include Prostate Cancer Treatment and Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Vitamin D Research Studies (3 papers). J. Medioni is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Vitamin D Research Studies (3 papers). J. Medioni collaborates with scholars based in France, Belgium and Germany. J. Medioni's co-authors include Stéphane Oudard, Christine Chevreau, Peter Stopfer, Odile Launay, Véronique Dièras, Ida Iurisci, Pierre Loulergue, Pierre Lebon, Michael Merger and Sophie Grabar and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. Medioni

11 papers receiving 88 citations

Peers

J. Medioni
Victor R. Vaz United States
D. Nitti Italy
Jean-Philippe Oster France
Yaiza Senent Spain
Giovanni Bocchialini Italy
Sarbajit Mukherjee United States
Martin Schönlein Germany
Marc Cucurull Spain
J. Remon Masip France
Yuye Zhang China
Victor R. Vaz United States
J. Medioni
Citations per year, relative to J. Medioni J. Medioni (= 1×) peers Victor R. Vaz

Countries citing papers authored by J. Medioni

Since Specialization
Citations

This map shows the geographic impact of J. Medioni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Medioni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Medioni more than expected).

Fields of papers citing papers by J. Medioni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Medioni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Medioni. The network helps show where J. Medioni may publish in the future.

Co-authorship network of co-authors of J. Medioni

This figure shows the co-authorship network connecting the top 25 collaborators of J. Medioni. A scholar is included among the top collaborators of J. Medioni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Medioni. J. Medioni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Daban, A., Laura Phan, Antonin Saldmann, et al.. (2023). Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs). OncoImmunology. 12(1). 2204754–2204754. 21 indexed citations
2.
Brachet, Pierre-Emmanuel, Michel Fabbro, Alexandra Léary, et al.. (2017). A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC). Annals of Oncology. 28. v347–v347. 4 indexed citations
3.
Droz, Jean‐Pierre, J. Medioni, Christine Chevreau, et al.. (2014). Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. Anti-Cancer Drugs. 25(9). 1081–1088. 12 indexed citations
4.
Loulergue, Pierre, Jérôme Alexandre, Ida Iurisci, et al.. (2011). Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. British Journal of Cancer. 104(11). 1670–1674. 22 indexed citations
5.
6.
7.
8.
Medioni, J., Joseph Kerger, J.-L. Canon, et al.. (2009). A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 27(15_suppl). 5153–5153. 1 indexed citations
9.
Oudard, Stéphane, et al.. (2007). What is the real impact of bone pain on survival of hormone-refractory prostate cancer (HRPC) patients treated with docetaxel?. Journal of Clinical Oncology. 25(18_suppl). 5149–5149. 2 indexed citations
10.
Oudard, Stéphane, Eugéniu Banu, F. Scotté, et al.. (2005). Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results. Journal of Clinical Oncology. 23(16_suppl). 4634–4634. 8 indexed citations
11.
Bennouna, Jaafar, J. Medioni, Frédéric Rolland, et al.. (2005). Phase I clinical trial of BromoHydrin PyroPhosphate, BrHPP (Phosphostim), a Vγ9Vδ2 T lymphocytes agonist in combination with low dose Interleukin-2 in patients with solid tumors. Journal of Clinical Oncology. 23(16_suppl). 2536–2536. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victor R. Vaz Breakdown of academic impact, for papers by D. Nitti Breakdown of academic impact, for papers by Jean-Philippe Oster Breakdown of academic impact, for papers by Yaiza Senent Breakdown of academic impact, for papers by Giovanni Bocchialini Breakdown of academic impact, for papers by Sarbajit Mukherjee Breakdown of academic impact, for papers by Martin Schönlein Breakdown of academic impact, for papers by Marc Cucurull Breakdown of academic impact, for papers by J. Remon Masip Breakdown of academic impact, for papers by Yuye Zhang
Rankless by CCL
2026